It is quite clear that the current anthrax
military vaccine does NOT
work. There have NEVER been ANY efficacy studies
as the following text is taken verbatim from the December
13, 1985, issue of the Federal Register states.
It reports on the findings of an independent
civilian advisory panel that considered the evidence for the
safety and efficacy of vaccines available in the 1970s. The
end of the document reports FDA's actions in response to the
panel's recommendations. The entire report is 115 pages long
(pages 51002 through 51117). This report is taken from a US
military web site.
Efficacy
The best evidence for the efficacy of
anthrax vaccine comes from a placebo-controlled field trial
conducted by Brachman (Ref. 1) covering four mills processing
raw imported goathair into garment underlinings. The study
involved approximately 1,200 mill employees of whom about
40 percent received the vaccine and the remainder received
the placebo or nothing. The average yearly incidence of clinical
anthrax in this population was 1 percent.
During the evaluation period, 26 cases
of anthrax occurred. Twenty-one had received no vaccine, four
had incomplete immunization and one had complete immunization.
Based upon analysis of attack rates per 1000 person-months,
The vaccine
was calculated to give 93 percent protection against cutaneous
anthrax.
Inhalation
anthrax occurred too infrequently to assess the protective
effect of the vaccine against this form of the disease.
Department
of Health and Human Services Food and Drug Administration,
Federal Register Vol. 50, No. 240 December 13, 1985, Part
II
Dr. Mercola's Comment:
Folks PAY ATTENTION this one the statement
in red is the KEY.
The US Military vaccine has NEVER been
tested against inhalation anthrax. That is the type that will
be the most devastating. It has only been tested against cutaneous
(skin) anthrax.
In simpler terms, this means the US
human approved anthrax vaccine is virtually worthless against
biological terrorism. They were able to get away with this
nonsense as the vaccine was introduced in 1970 which is two
years before efficacy studies were required before a vaccine
could be released.
The US vaccine was used only by several
thousand people until 1990. There have been no controlled
clinical trials in humans of the efficacy of the currently
licensed US vaccine.
The article does go on to state indications
where the vaccine should not be administered.
1. A history of clinical anthrax
infection which may enhance the risk of severe reactions.
2. Severe systemic reactions with
marked chills and fever following a prior injection - in
this case further attempts at immunization should be abandoned.
3. The presence of acute respiratory
disease or other febrile illnesses in order not to confuse
the cause of further fever.
4. Therapy with corticosteroids
or other immunosuppressive agents - in this case immunization
should be deferred until such therapy has been completed.
If on a long-term therapy, a more intensive immunization
schedule should be considered.
5. Pregnancy is a Category C. DO
NOT ADMINISTER.
Reference
Brachman, P.S., H. Gold, S.A.
Plotkin, R. Fekety, M. Werrin, and N.R. Ingraham, "Field
Evaluation of a Human Anthrax Vaccine," American Journal
of Public Health, 52:632-645, 1962
